Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bulge progenitor cells show promise for regenerating hair follicles and increasing hair density.

This study analyzed the swelling behavior of human hair during permanent waving treatment, finding that both the microstructure and macrostructure of intermediate filaments swell simultaneously at the initial stage, and while partially destructed by reduction, they are considerably restored through oxidation.

This study observed that PCE-DP may improve skin pigmentation by increasing epidermal turnover and inhibiting melanin uptake and inflammation in human epidermal keratinocytes.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

Applying pseudoceramide improved skin and hair health.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

This study found that poly(butylene citramalate-co-butylene succinate) copolymers exhibit high toughness, recyclability, degradability, and biocompatibility, achieving complete wound healing with skin and hair follicle regeneration in 7 days.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This study found that the revised BASP classification for pattern hair loss, which addresses certain limitations of the original, could serve as an alternative option despite a decrease in clinical accuracy and ease of use.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

This study suggests that hair loss disorders like Marie Unna hereditary hypotrichosis may result from mutations that disrupt post-transcriptional regulation of HR protein expression by PCPB2 interacting with Hr mRNA.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This review provides a practical approach to diagnosing pseudopelade of Brocq and updates on treatment options but reports no new clinical results.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

This study found that biodegradable hyperbranched polyesters improved the solubility and loading capacity of hydrophobic drugs, with complete pyrene release achieved in 16 days under enzymatic conditions.

This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

PCFCL may have unrecognized subtypes and needs more research.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study identified ISPP-Rb, a novel immuno-stimulatory complex from Royoporus badius, that significantly activates murine macrophage cells and induces multiple proinflammatory cytokines.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

This study reports the first cases of recessive KRT17-related pachyonychia congenita involving all ectodermal derivatives in seven members of two consanguineous Pakistani families.

This study identified seven novel CYP17A1 inhibitor scaffolds as potential leads for treating polycystic ovary syndrome through an in silico approach, demonstrating favorable interactions, drug-like properties, and predicted bioactivities warranting further experimental validation.